Fritextsökning
Innehållstyper
-
Sobi fick positivt utlåtande inom sällsynta njursjukdomar
Särläkemedelsbolaget Sobis läkemedel Aspaveli rekommenderas för godkännande i EU för två ovanliga njursjukdomar.
-
Developing rapid diagnostics for sepsis – “Every hour counts”
Finding the right antibiotic in the right dose – with an ultra-fast analysis method. Gradientech's product solution is currently used in routine diagnostics at ...
-
New ATMP center inaugurated: “In the future, we will see cell and gene therapies in all clinics”
Karolinska Institutet and Karolinska University Hospital’s new ATMP center was inaugurated in Flemingsberg, south of Stockholm. “The ATMP Center is not just a p...
-
Medical device quality assurance
Recordings from ZEISS Quality Innovation Days.
-
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
-
Conjugate Planes in Microscopy
Knowledge Article from ZEISS.
-
Claims of life science companies fleeing abroad is a myth according to survey
The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.
-
Scale Up Your Image Analysis
ZEISS arivis Hub for accelerated analysis and faster results.
-
Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma
Webinar | March 13, 2024, 12 PM EST.
-
Partial court victory for entrepreneur who lost his company
Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...
-
A vaccine the world is waiting for: “It can change the lives of many”
A Solna laboratory is developing a vaccine that could save the lives of countless children in low- and middle-income countries. “Working on something that can m...
-
Optimize Your Visibility
ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.
-
Non-destructive testing and assembly control
Assess complete assembly.
-
Astra Zeneca pauses multi-million investment in the UK
Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.
-
Festo Expands its Portfolio with Multilayer Manifolds
Manufacturers of medical and laboratory equipment now receive solutions from a single source
-
40,000 DNA extractions daily
, customers in the seed industry can collect DNA from up to 40,000 samples per day.
-
Webinar: Support Trial Patients Transitioning to the Commercial Space
Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.
-
Anna Törner: ”If I fall seriously ill, I’ll move to Finland”
”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.
-
New diagnostic rules raise concerns
In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagno...
-
Life science trends 2025 – The economy
Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...
-
USA och Storbritannien i nytt avtal – nolltullar för läkemedel
USA och Storbritannien har enats om ett handelsavtal som avskaffar amerikanska tullar på brittiska läkemedel och medicintekniska produkter. I utbyte lovar Storb...
-
Don't miss out on this unique opportunity
ZEISS QUALITY INNOVATION SUMMIT October 22 - 24 in Berlin.
-
Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow
Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...
BREAKING